Publications

Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here: MS May et al.

MS May, W Park, EM O’Reilly

Tumor Microenvironment: Insights from Multiparametric MRI in Pancreatic Ductal Adenocarcinoma

Paudyal R, Russell J, Lekaye HC, Deasy JO, Humm JL, Awais M, Nadeem S, Do RKG, et al.

Universal Germline Genetic Testing after a Diagnosis of Cancer

ZK Stadler, A Maio, A Khurram, K Arora, C Bandlamudi, YL Liu, Y Kemel, ...

111O The mechanism of mismatch repair deficiency (MMRd) informs survival outcomes derived from immune checkpoint blockade (ICB) across MMRd solid tumors

V Randrian, K Sweeney, E Alouani, P Johannet, O Artz, MB Foote, ...

1712P Efficacy and safety of cabozantinib (CABO) for advanced lung and thymic neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of phase III …

EM Wolin, T Zemla, S Geyer, JR Strosberg, TR Halfdanarson, N Trikalinos, ...

2137P ASP2138 monotherapy in patients (pts) with claudin 18 isoform 2 (CLDN18. 2)+, advanced solid tumors: phase I/Ib trial

K Shitara, HJ Choi, F Dayyani, S Kazmi, I Korakis, RH Moy, EM O'reilly, ...

2228P the SHARON trial: melphalan, BCNU, hydroxocobalamin, ascorbic acid, and stem cells for pancreatic and breast cancer and an inherited BRCA/PALB2 mutation

KH Yu, P Dahi, CD Weekes, YB Chen, J Glazier, A Glazier, S Giralt, ...

350P IDH2-mutated cholangiocarcinoma: a case series highlighting challenges and insights

L Al Mahmasani, JJ Harding, R Thummalapalli, D Khalil, A Yaqubie, ...

384TiP quemliclustat and chemotherapy in previously untreated patients with metastatic pancreatic ductal adenocarcinoma: PRISM-1, a randomized, placebo-controlled, phase III trial

TM Mercade, T Bekaii-Saab, K Feeney, EM O'Reilly, S Pant, JO Park, ...

707 Mechanism of MLH1 inactivation predicts benefit to dual immune checkpoint blockade in mismatch repair deficient tumors

B Rousseau, V Randrian, K Sweeney, M Khushman, E Alouani, ...

752P Clinical outcome of patients (pts) with sporadic vs Lynch syndrome-related stage III colon carcinoma (CC) with deficient mismatch repair (dMMR) treated in a randomized …

FA Sinicrope, FS Ou, A Reinacher-Schick, RJ Behrens, WR Peters, ...

A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)

ZA Wainberg, D Melisi, T Macarulla, R Pazo Cid, SR Chandana, ...

Abstract A088: Genomic Scar to Immune Signals: Translational Insights from the POLAR Trial Reveal POLQ-Driven Immunogenicity in HRD Pancreatic Cancer

W Park, C O'Connor, M Hilmi, S Umeda, R Sharma, K Soares, ...

Abstract A097: Impact of socioeconomic status on survival outcomes in patients with stage IV pancreatic adenocarcinoma: A race/ethnicity controlled analysis

A Erakky, S Nandakumar, M Waters, J Duque-Jimenez, A Awuah, M Lao, ...

Abstract A113: Cachexia and Depression in Pancreatic Cancer (PC) Associate with Myeloid Inflammation and Tumor-Intrinsic Metabolic Stress

J Song, M Hilmi, C O'Connor, H Martirosova, J Schoenfeld, A Hilmi, ...

Abstract A125: Tumor cell plasticity, stromal rewiring, and clonal T cell expansion define response and resistance to combined PARP and PD-1 blockade (POLAR) in pancreatic cancer

M Hilmi, J Park, W Mckerrow, S Umeda, C O'Connor, Y Elhanati, ...

Abstract B044: Black and Hispanic patients with pancreatic ductal adenocarcinoma (PDAC) have worse overall survival than Asian and White patients with PDAC, despite having more …

JB Duque-Jimenez, AN Awuah, A Erakky, S Nandakumar, M Waters, ...

Abstract B047: DNA Damage Repair (DDR) Variants Beyond BRCA/PALB2 in Pancreatic Adenocarcinoma (PDAC): Evaluation of Significance

CA O'Connor, JW Lee, E Harrold, AL Richards, D Muldoon, ...

Abstract CT192: Orally administered MOMA-313 as monotherapy or combination therapy in participants with advanced or metastatic solid homologous recombination (HR)-deficient …

A Patnaik, W Abida, KA Reiss, J De Bono, R McKay, AH Bryce, ...

Adjuvant cytotoxic chemotherapy may not be associated with a survival advantage for resected intrahepatic cholangiocarcinoma

J Sharib, KE Rhodin, A Liu, S McIntyre, A Bartholomew, S Masoud, ...

Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort

Keane F, O'Connor C, Moss D, Chou JF, Perry MA, Crowley F, Saxena P, Chan A, et al.

Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)

Tsang ES, Shi Q, Olive K, Collisson E, Dixon JG, Cusnir M, Winograd R, Botta GP, et al.

ASO Visual Abstract: Blood Sample Collection in Randomized Controlled Trials for Biomarker Discovery and Validation: Experience of the PREOPANC-2 Trial

EN Dekker, QP Janssen, JL van Dam, GJ Strijk, EMM Verkolf, S Kandala, ...

ASO Visual Abstract: Survival Outcomes and Genetic Characteristics of Resected Pancreatic Acinar Cell Carcinoma

AB Blair, SN Radomski, J Chou, M Liu, TC Howell, W Park, EM O’Reilly, ...

Association between empirical dietary inflammatory pattern (EDIP) and survival in patients with stage III colon cancer: Findings from CALGB/SWOG 80702 (Alliance).

SK Char, Q Shi, T Zemla, C Ma, E Cheng, P Kumthekar, KA Guthrie, ...

Association of inflammation with depression in pancreatic ductal adenocarcinoma.

J Song, DH Hong, S Park, M Hilmi, JD Schoenfeld, A Hilmi, H Martirosova, ...

Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Updated safety and efficacy of a phase 1b/2 study …

KH Lim, RA Safyan, K Perez, KR Spencer, EM O'Reilly, AH Ko, A Shergill, ...

Best practices for delivering neoadjuvant therapy in pancreatic ductal adenocarcinoma

JM Cloyd, A Sarna, MJ Arango, SE Bates, MS Bhutani, M Bloomston, ...

Biomarkers associated with outcomes from OPTIMIZE-1: CD40 agonist mitazalimab with mFOLFIRINOX in patients with untreated metastatic pancreatic cancer.

PA Cassier, JL Van Laethem, I Borbath, T Macarulla, KP Geboes, ...

Blood sample collection in randomized controlled trials for biomarker discovery and validation: experience of the PREOPANC-2 trial

EN Dekker, QP Janssen, JL van Dam, GJ Strijk, EMM Verkolf, S Kandala, ...

Body mass index and somatic variants in biliary tract cancers.

L Al Mahmasani, JF Chou, M Capanu, A Srivastava, CS Sigel, ...

Carbohydrate antigen 19-9 (CA19-9) response after induction FOLFIRINOX for locally advanced pancreatic cancer identifies patients who may benefit from surgical exploration …

EN Dekker, D Van Klaveren, EMM Verkolf, RF De Wilde, MG Besselink, ...

CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1

JL Van Laethem, K Geboes, I Borbath, TM Mercade, A Lambert, P Cassier, ...

Characteristics of long-term survivors and impact of dose adjustments in first-line NALIRIFOX treatment for metastatic pancreatic ductal adenocarcinoma: post hoc analyses of …

V Chung, A Patel, Y Liu, M Kochenderfer, N Natarajan, GR Williams, ...

Clinical landscape of cell free DNA alterations in patients with advanced biliary tract cancer treated with targeted therapies.

R Thummalapalli, M Darmofal, K Seier, DN Khalil, HS Walch, J Shia, ...

Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in Biliary Tract Cancer

Cowzer D, Darmofal M, Seier K, Thummalapalli R, Walch H, El Dika I, Khalil DN, Park W, et al.

Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma

Keane F, Saadat LV, O'Connor CA, Chou JF, Bowman AS, Xu F, Crowley F, Debnath N, et al.

Clinico-genomic characterization of PALB2-mutated pancreatic adenocarcinoma.

JW Lee, CA O'Connor, E Harrold, AL Richards, F Velez-Cortes, D Moss, ...

Clinicogenomic comparison of patients with liver-avid/lung-adverse and lung-avid/liver-adverse patterns of metastases highlights commonalities across cancer types

J Nguyen, WK Chatila, P Manca, H Walch, S Nandakumar, P Razavi, ...

Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival

Varghese AM, Perry MA, Chou JF, Nandakumar S, Muldoon D, Erakky A, … Park W, …

Clinicopathologic and allele-specific analysis of germline ATM alterations in a pan-cancer cohort.

M Repetto, D Muldoon, P Selenica, K Arora, YL Liu, M Carlo, L Banaszak, ...

Complementary Chinese Herbal Medicine Use and Gastrointestinal Cancers: A Scoping Review of Usage Patterns and Survival Outcomes in Taiwanese Population-Based Studies

CS Lam, E Kwag, S Chimonas, SL Cytryn, YN Hou, HR Yen, ED Kantor, ...

DESCRIBING HEMATOLOGICAL ADVERSE EVENTS (AES) AND UTILIZATION OF GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) AMONG PATIENTS RECEIVING NALIRIFOX FOR METASTATIC PANCREATIC …

K Sampat, M Cusnir, P Cockrum, A Sosinksy, AM Siney, E O'Reilly

Early-Phase Trials in Journal of Clinical Oncology

Stinchcombe TE, Fleming GF, Craddock C, Ko AH, O'Reilly EM, Maki RG

Effect of dose adjustments on overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX: A post hoc analysis of NAPOLI 3.

AJ Patel, AA Laursen, P Cockrum, Y Liu, A Surinach, W Rhodes, L Zhang, ...

Efficacy and safety of cabozantinib for advanced gastrointestinal (GI) neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of the phase 3 CABINET …

JR Strosberg, TJ Zemla, SM Geyer, MV Knopp, S Behr, S Pulsipher, ...

Efficacy of zenocutuzumab in NRG1 fusion-positive cancer

AM Schram, K Goto, DW Kim, T Macarulla, A Hollebecque, EM O’Reilly, ...

Evaluating the relative treatment efficacy of CD40 agonist mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC …

EM O’Reilly, T Macarulla, L Dahan, I Borbath, PA Cassier, F Guelfucci, ...

Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2

S Lucotti, Y Ogitani, CM Kenific, J Geri, YH Kim, J Gu, U Balaji, L Bojmar, ...

Feasibility of Endoscopic Ultrasound-Guided Tissue Acquisition for Next-Generation Sequencing in Pancreatic Cancer Patients

SE Lee, D Kim, N Zbib, C Sigel, E Vakiani, EM O'reilly, K Yu, W Jarnagin, ...